Nephros, Inc.NEPHNASDAQ
Loading
R&D Expenses Over TimeStable
Percentile Rank71
3Y CAGR+2.2%
5Y CAGR-13.5%
Studio
Year-over-Year Change

Research and development spending

3Y CAGR
+2.2%/yr
vs -5.0%/yr prior
5Y CAGR
-13.5%/yr
Recent acceleration
Acceleration
+7.2pp
Accelerating
Percentile
P71
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
2 yr
Consecutive growthStable
PeriodValueYoY Change
TTM$1.34M+47.8%
2024$906000.00+3.8%
2023$873000.00-30.4%
2022$1.25M-16.2%
2021$1.50M-45.7%
2020$2.76M-10.7%
2019$3.09M+100.8%
2018$1.54M+53.6%
2017$1.00M-7.1%
2016$1.08M-